Prepare an NDA or ANDA annual report and distinguish BLA requirements

How do you prepare an NDA or ANDA annual report?

Use the U.S. approval anniversary and §314.81(b)(2) to define the interval and required content. Reconcile significant findings, distribution by the specified product identifiers and dosage units, labeling and manufacturing changes, clinical/nonclinical information and study status. Include the required Form FDA 2252 and distinguish BLA-specific obligations before reusing a template.

Before you begin

NDA/ANDA annual reports under 314.81(b)(2), with explicit BLA boundaries under 601.12; BLA obligations are not a wholesale copy of Part 314.

What you will prepare: A controlled annual package with source-backed changes, distribution and study-status cross-references.

Establish the approved application and interval

For an NDA/ANDA, retrieve the U.S. approval anniversary, last annual report, approved product scope and interval records. 314.81(b)(2) specifies the report within 60 days of the anniversary and a completed Form FDA 2252. Use the current form and electronic-submission instructions, not historical paper-copy directions embedded in older text.

For a BLA, assess the actual reporting obligations: 601.12(d) addresses annual-report changes, 601.12(f)(3) addresses specified labeling changes, and 601.70 addresses applicable postmarketing-study progress. Do not require every NDA annual-report item for a BLA merely because the catalog presents the same family.

1.13.1–1.13.3 and 1.13.7: summarize evidence and resulting action

Nonclinical (1.13.1): collect new toxicological findings and the relevant unpublished reports or summaries of published reports. Identify the ingredient/product relationship, study scope and significance; do not omit an unfavorable finding because no label change has yet been proposed.

Clinical pharmacology (1.13.2): reconcile new biopharmaceutic, PK and pharmacology information with the relevant published or completed unpublished clinical work. State the population and evidence limitations, and identify whether the finding changes an existing conclusion.

Safety (1.13.3): summarize significant new information that may affect safety, effectiveness or labeling and the actions taken or planned. Coordinate with the periodic and expedited safety-reporting owners; this annual report is not their replacement. Address the regulation's pediatric information where applicable.

Other significant information (1.13.7): explain material developments outside the preceding categories and their disposition. The report should distinguish “reviewed, no new relevant information” from “the owner has not supplied the data.” Include the relevant clinical material according to 314.81(b)(2)(vi), rather than every publication mentioning the drug.

1.13.4: produce a dated labeling-change chronology

Collect the prior and current controlled labeling, implementation records and related submissions. For the NDA/ANDA annual report, provide the current labeling material described by the rule and a chronological summary of implemented changes, or the required no-change statement when supported.

A useful working table includes labeling component, prior version, new version, implementation date, nature of change and regulatory submission/decision reference. Distinguish the date text was drafted, the date FDA acted and the date it was implemented. The annual summary does not make a labeling change eligible for annual reporting if another reporting category applies. Apply the BLA-specific labeling provisions separately.

1.13.5–1.13.6: reconcile changes with their reporting category

For manufacturing changes, obtain the change-control register and the regulatory assessment for each implemented change. Describe changes eligible for the annual-report route, with dates and supporting scientific references. Also summarize relevant new quality findings and their impact. A change's inclusion in this report does not replace a supplement required before or after implementation under the applicable change provisions.

For microbiological changes, identify the actual process/control change or significant finding, product/site/batches affected and the reason it matters. Reconcile this with stability, investigations, deviations and other reports. In a BLA, use the 601.12 framework and its product-quality risk criteria; do not classify a biologic process change by copying a small-molecule example.

1.13.11: report product units, not revenue or shipment totals without context

Reconcile quantity distributed under the approved NDA/ANDA by the required NDC, strength or potency and dosage units, distinguishing domestic and foreign quantities. Obtain the source extract and its definitions: units, packages, bottles or vials are not interchangeable. The regulation does not require pricing information. Address authorized-generic information when applicable.

Have the supply-data owner document how adjustments and source-system conventions affect the reported totals. Investigational supply or product under another application should not silently enter the totals. A pharmaceutical's biological nature alone does not make this NDA/ANDA requirement a universal BLA distribution report; establish any applicable BLA reporting separately.

1.13.14: close the report with a factual open-business log

The NDA/ANDA open-regulatory-business log is optional under 314.81(b)(2)(ix). If included, list unresolved correspondence in either direction, dates and references, the requested next action and the owner. Do not list a received FDA response as unanswered simply because the internal task is still open.

Fictional editorial exercise: a distribution table labels 10,000 bottles as 10,000 tablets, and the labeling summary uses approval dates as implementation dates. Reconcile the source definitions and actual change records. If the units or implementation evidence are absent, those outputs remain unresolved. Changing the application from NDA to BLA requires reassessing the content map, not changing only the cover-page acronym.

Check the units and dates that most easily distort the report

Build a distribution reconciliation before writing the summary. Keep the source extract, unit definitions and transformation logic so the reviewer can reproduce the reported quantity. The working table below is an editorial aid; adapt it to the actual presentation and data system.

The example establishes a conversion, not a universal reporting convention for all dosage forms. A vial, tablet and milliliter are different measures. Do not turn a packaging example into a rule that every injectable must be reported as milliliters, or combine strengths into one total that loses the required breakdown. Resolve returns and other adjustments with the data owner rather than silently inventing a net-distribution definition.

For labeling, maintain three distinct dates where applicable: document revision, relevant regulatory submission or action, and implementation. The required chronology concerns implemented changes. A draft revised in February, an agency action in April and implementation in May are not one event. Use the actual implementation record, and identify the correspondence that supports the change without implying that every change required the same route.

Review exercise: the supply table reports ten bottles as ten dosage units, while the labeling narrative dates a change to the day the writer finished the draft. Correct both from source records. If those records are unavailable, retain the gap for resolution; neither a plausible conversion nor a guessed date is suitable evidence.

Keep authorized-generic entry/exit information distinct from ordinary distribution totals, with the required separate treatment of each dosage form or strength. For quality changes, preserve the reporting-category assessment: an annual-report description cannot cure an omitted required supplement. Reconcile study entries with the postmarketing-status guide and confirm the application clock using the annual-report route guide.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides